Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management.

Cinzia CordioliGraziella CallariRoberta FantozziFrancesca CarusoGiuseppe MartucciSanta MascaraValentina Zipoli

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)

Patient education and counseling play a key role in promoting adherence to treatment especially in the first months also in patients switching from nonpegylated IFNs to peginterferon beta-1a.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
healthcare
chronic kidney disease
prognostic factors
case report
patient reported
metabolic syndrome
quality improvement
smoking cessation
weight loss
hepatitis c virus
combination therapy
human immunodeficiency virus